Related Experiment Video
Updated: Jun 27, 2026
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
1USC/Norris Cancer Center, 1441 Eastlake Ave Rm 3460, Los Angeles, CA 90033, United States. douer_d@ccnt.hsc.usc.edu
Insights
Asparaginase improves pediatric acute lymphoblastic leukemia (ALL) outcomes. Its use in adults is unclear due to toxicity concerns and comparable results without it, necessitating further research.
Area of Science:
- Oncology
- Hematology
Background:
- Pediatric acute lymphoblastic leukemia (ALL) outcomes have significantly improved with asparaginase-containing regimens.
- Adult ALL treatment protocols incorporate asparaginase, but it's linked to increased toxicity in older patients.
Purpose of the Study:
- To evaluate the necessity and role of asparaginase in adult acute lymphoblastic leukemia treatment.
- To address the lack of randomized trials investigating asparaginase in adult ALL.
Main Methods:
- Review of existing adult ALL treatment protocols and outcomes.
- Analysis of factors influencing asparaginase efficacy and toxicity in adults.
Main Results:
- Adult regimens without asparaginase have demonstrated comparable outcomes to those including it.
- No randomized trials specifically for asparaginase in adult ALL have been conducted.
Conclusions:
- The definitive role of asparaginase in adult ALL remains uncertain due to toxicity and comparable outcomes without it.
- Further investigation is required into optimal dosing, scheduling, and formulation of asparaginase for adult patients, considering toxicity and immunogenicity.
Abstract:
The outcome of pediatric acute lymphoblastic leukemia (ALL) has improved dramatically over the last 40 years through a systematic approach of well-designed large trials including use of asparaginase. Although asparaginase has been incorporated with other drugs in adult ALL protocols, it has been associated with more toxicities in older patients resulting in caution in the inclusion of asparaginase-containing regimens for adults. Consequently, to date, no randomized trials with asparaginase have been performed in adults. Furthermore, adult regimens that do not include asparaginase have shown comparable outcomes to regimens with asparaginase, which makes the necessity of asparaginase in adult regimens unclear. There are several other factors which influence the role of asparaginase use in adults, including the level and sustainability of asparagine depletion, schedule, dosing, and form of asparaginase and the consequent toxicities and immunogenicity reactions.
More Related Videos
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:19Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...